Shenzhen Salubris Pharmaceuticals Co. Ltd. (002294)

Overview

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a prominent pharmaceutical and medical device company based in Shenzhen, China. Since its incorporation in 1998, the company has been dedicated to the research, development, production, and sale of a wide range of medicines and medical devices. Operating as a subsidiary of Salubris Pharmaceuticals Co., Ltd., its extensive product portfolio spans various therapeutic fields, including thrombosis, hypertension, osteoporosis, infections, and more. Moreover, it has a strong commitment to innovation in the therapeutic areas of cardiovascular and cerebrovascular diseases through the development of interventional medical devices.

Products and Services

• Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets

  These are all innovative medications currently in phase III clinical trials intended for the treatment of hypertension. Each drug demonstrates Shenzhen Salubris Pharmaceuticals Co., Ltd.'s expertise in developing effective therapies for managing blood pressure conditions.

• Enarodustat

  A promising drug for the treatment of renal anemia, showcasing the company's commitment to addressing chronic kidney disease complications.

• SAL056, SAL001, SAL023

  Medications in development for the treatment of osteoporosis, which highlight the company's focus on bone health and the prevention of bone-related diseases.

• Fotagliptin and SAL015

  These are under phase III clinical trials for diabetes, indicating the company's involvement in the fight against this widespread metabolic disorder.

• Sacubitril Allisartan Calcium and SAL007 for Chronic Heart Failure; SAL003 for Hypercholesterolemia; SAL0114 for Depressant Indications

  These medications, in various stages of development, demonstrate Shenzhen Salubris Pharmaceuticals' efforts to address critical aspects of cardiovascular health and mental well-being.

• SAL023, SAL0112, and SAL008

  Preclinical products targeting osteoporosis, diabetes, and tumors, respectively, showing the broad scope of the company's research and development pursuits in critical health areas.

• Intracranial Segment of Vertebral Artery Stent, SaExtenVena Cava Filter, Microneedle Perfusion Absolute Ethanol Delivery System, and LAMax LAAC Left Atrial Appendage Occluder

  These are among the interventional medical devices developed by the company. Ranging from neurology to peripheral vascular and structural heart disease interventions, these devices underscore Shenzhen Salubris Pharmaceuticals' innovation in medical technology to improve patient outcomes.